AUTHOR: Fred F. Ferri, MD
Herpes simplex is a viral infection caused by the herpes simplex virus (HSV). HSV-1 is associated primarily with oral infections, and HSV-2 causes mainly genital infections. However, either type can infect any site. After the primary infection, the virus enters the nerve endings in the skin directly below the lesions and ascends to the dorsal root ganglia, where it remains in a latent stage until it is reactivated.
| ||||||||||||||||||||||||||||||||
Figure E1 Herpetic gingivostomatitis.
Multiple erosions with crusting. Note the associated lesions involving the chin.
From Paller AS, Mancini AJ: Hurwitz clinical pediatric dermatology: a textbook of skin disorders of childhood and adolescence, ed 5, Philadelphia, 2016, Elsevier.
Figure E2 Primary herpes simplex.
A, Scattered erosions covered with exudate. B, Numerous erosions appeared 4 days after contact with an asymptomatic carrier.
From Habif TP: Clinical dermatology, ed 4, Philadelphia, 2004, Mosby.
Erythematous erosions clustered on the right lower lip in a patient with labial herpes. This young girl also had herpes-associated erythema multiforme.
From Paller AS, Mancini AJ: Hurwitz clinical pediatric dermatology: a textbook of skin disorders of childhood and adolescence, ed 5, Philadelphia, 2016, Elsevier.
TABLE 1 Topical and Oral Antiviral Medications Used for Herpes Simplex Virus Infections∗
| Drug | Formulation | Regimen | Indication/Comment |
|---|---|---|---|
| Topical | |||
| Acyclovir | 5% cream (2 g, 5 g) | Apply 5 times/day | Recurrent HL; A: ≥12 yr; 4 days; Rx |
| 5% ointment (15 g, 30 g) | Apply 6 times/day | Initial GH, localized HSV; A: Adults; 7 days; Rx | |
| Penciclovir | 1% cream (1.5 g, 5 g) | Apply q2h (awake) | Recurrent HL; A: ≥12 yr; 4 days; Rx |
| Docosanol | 10% cream (2 g) | Apply 5 times/day | HL; A: ≥12 yr; treat until healed; OTC |
| Oral (all Rx) | |||
| Acyclovir | 200-mg capsule | A: ≥2 yr | |
| 400-mg, 800-mg tablet | |||
| 200-mg/5-ml susp | |||
| 200 mg 5 times/day | Initial GH; 10 days | ||
| 200 mg 5 times/day | Recurrent GH; 5 days | ||
| 400 mg 2 times/day | Suppression, recurrent GH; up to 12 mo, then reevaluate | ||
| Famciclovir | 125-, 250-, 500-mg tablet | A: ≥18 yr | |
| 1500-mg single dose | Recurrent HL | ||
| 1000 mg 2 times/day | Recurrent GH; 1 day | ||
| 250 mg 2 times/day | Suppression, recurrent GH; up to 12 mo | ||
| Valacyclovir | 500-mg, 1-g caplet | A: Adults and ≥12 yr for HL | |
| 1 g 2 times/day | Initial GH; 10 days | ||
| 500 mg 2 times/day | Recurrent GH; 3 days | ||
| 500 mg-1 g once daily | Suppressive GH | ||
| 2 g 2 times/day | HL; 1 day; both adults and children ≥12 yr | ||
A, Approved; GH, genital herpes; HL, herpes labialis; HSV, herpes simplex virus; OTC, over-the-counter; Rx, by prescription.
∗Approved indications and regimens listed; often used off-label.
From Paller AS, Mancini AJ: Hurwitz clinical pediatric dermatology: a textbook of skin disorders of childhood and adolescence, ed 5, Philadelphia, 2016, Elsevier.
TABLE 2 Antiviral Treatment for Herpes Simplex Virus in the Nonpregnant Patient
| Antiviral Agent | |||
|---|---|---|---|
| Indication | Valacyclovir | Acyclovir | Famciclovir |
| First clinical episode | 1000 mg bid, 7-10 days | 400 mg tid; or 200 mg five times/day, 7-10 days | 250 mg tid, 7-10 days |
| Recurrent episodes | 1000 mg daily, 5 days; or 500 mg bid, 3 days | 800 mg bid, 5 days; or 800 mg tid, 2 days | 125 mg bid, 5 days 500 mg once then 250 mg bid, 2 days; 1000 mg bid, 1 day |
| Daily suppressive | 1000 mg daily (≥10 recurrences/yr) or 500 mg daily (≤9 recurrences/yr) | 400 mg bid | 250 mg bid |
bid, Twice per day; tid, three times per day.
Data from Workowski KA, Bolan GA, Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines, 2015, MMWR Recomm Rep 64(RR-03):1-137, 2015; Gershenson DM et al: Comprehensive Gynecology, ed 8, Philadelphia, 2022, Elsevier.